logo
logo
  • About us
    • Reig Jofre in brief
    • Strategic pillars
    • Company history
    • Locations
  • Products
    • Product categories
    • Pharmaceutical Technologies
      • Antibiotics
      • Injectable products
      • Others
    • Specialty Products
      • Skin, Hair & Nail Health
      • Joint Health & Pain
      • Women’s Health
      • Respiratory / ENT
      • Pediatrics
    • Consumer Healthcare
    • Healthcare professionals and consumers corner
  • R&D
    • R&D
    • Innovation in Collaboration
    • Pipeline
    • Joint projects
  • Services
    • CDMO services
    • CMO services
  • Investors
    • Information note
    • General information
    • Inside information
    • Other relevant information
    • Former relevant facts
    • Financial information
    • Corporate governance
    • General shareholders’ meetings
    • The share
    • Analysts covering the stock
    • Presentations
    • Webcasts
  • News
    • News and repository
    • Reig Jofre in the media (ES)
    • Subscription center
  • Social Responsibility
  • Contact
    • Contact form
    • Work with us
  • |
  • ES
  • EN

News

Transparency withour stakeholders

  • Show all
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

25 November 2019

Transactions within the share buy-back program

22 November 2019

Reig Jofre, Internationalization of Spanish Healthcare Activity Award

18 November 2019

Transactions within the share buy-back program

14 November 2019

Reig Jofre closes the third quarter of 2019 with an accumulated growth of 10% in sales and 17% in EBITDA

12 November 2019

Reig Jofre and Ojer Pharma obtain the first European authorization for the commercialization of their innovative antibiotic Impetine Gel

11 November 2019

Transactions within the share buy-back program

4 November 2019

Transactions within the share buy-back program

28 October 2019

Transactions within the share buy-back program

21 October 2019

Transactions within the share buy-back program

14 October 2019

Transactions within the share buy-back program

7 October 2019

Transactions within the share buy-back program

2 October 2019

Bioglan will manufacture LECIGON® for Lobsor Pharmaceuticals

30 September 2019

Transactions within the share buy-back program

23 September 2019

Transactions within the share buy-back program

16 September 2019

Transactions within the share buy-back program

9 September 2019

Transactions within the share buy-back program

2 September 2019

Transactions within the share buy-back program

19 August 2019

Transactions within the share buy-back program

5 August 2019

Transactions within the share buy-back program

29 July 2019

Transactions within the share buy-back program

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 15

Legal advice – Online store access for employees – RJF connected

© 2020 Laboratorio Reig Jofre

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Privacy Preference Center

Privacy Preferences